The NeuMedix Health Group consists of a number of individual companies with different boards and shareholders formed for specific purposes. These companies fall into two distinct groups - Investments and Technology. Under the directorship of Michael Issakidis, Anthony Dickson and Professor Max Reynolds the scope of the Investment and Technology group of companies varies from joint venture funding with innovators and inventors to complete commercialisation of a medical concept. The overarching emphasis is on innovation that is commercially viable and provides substantial benefit to the community. 

The companies within the group are: 

Investment Companies  

• NeuMedix Pty Ltd 
• NeuMedix Inc 
• NeuMedix Investments Pty Ltd
• NeuMedix Health Australasia Pty Ltd

 Technology Companies

• NeuMedix Biotechnology Pty Ltd
• NeuMedix Melacon Pty Ltd 
• NeuMedix Genvax Pty Ltd 
• NeuMedix Surgical Pty Ltd
• Australian Botanical BioScience (Cancer) Pty Ltd
• Australian Botanical BioScience (Dengue) Pty Ltd

COMPANY NEWS

Investment in US Alzheimer's technology

Jun 09: Blocking a brain-derived enzyme induces investment in University of ... more..

MAC face mask is a killer!

Jan 2009: It’s now a fact, M.A.C. kills bacteria on face masks for up to 7 days. Official tests ... more..

MAC now over the counter

Sept 2008: The effective MAC (Melaleuca Alternifolia Concentrate), a powerful anti-oxidant, is now available for sale “Over The Counter”.

Clinical Melanoma trials to commence for GENVAX

Sept 2008: Human ethics approval has been received for the clinical trials will take place in... More..

Wound treatment for Gangrene amputations

Sept 2008: 20,000 amputations are carried out each year in Taiwan due to diabetic gangrene ... More..

Ground breaking Dengue Project in Indonesia

August 2008: A successful “Control Hospital Based Study” showed Dengue Fever virus infection was destroyed within 3-4... More..

Prostate Cancer Study

August 2008: Prostate Cancer affects millions of Australian men and their families each year, and further research.. More..